Evidence map›Paper›PMID 37924953›Full record

ArticleJournal of the American Academy of Dermatology2024

Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma.

Daniel Y Kim, Susan M Swetter, Linden Huhmann, Matthew P Dizon, Jacqueline M Ferguson, Thomas F Osborne, Allyson C Spence, Amina Ziad, Nathanael Fillmore, Rebecca I Hartman

Abstract read
In one paragraph

Article in Journal of the American Academy of Dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel Y KimHarvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Susan M SwetterDepartment of Dermatology, Stanford University Medical Center, Palo Alto, California; Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
Linden HuhmannMassachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts.
Matthew P DizonDermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California; Center for Innovation to Implementation, Veterans Affairs Palo Alto Health Care System, Menlo Park, California.
Jacqueline M FergusonCenter for Innovation to Implementation, Veterans Affairs Palo Alto Health Care System, Menlo Park, California.
Thomas F OsborneVeterans Affairs Palo Alto Health Care System, Palo Alto, California; Department of Radiology, Stanford University School of Medicine, Palo Alto, California.
Allyson C SpenceDepartment of Medical Oncology, Stanford University Medical Center, Palo Alto, California.
Amina ZiadHarvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Nathanael FillmoreHarvard Medical School, Boston, Massachusetts; Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts; Department of Medicine, Veterans Affairs Boston Healthcare System, Boston, Massachusetts; Dana Farber Cancer Institute, Boston, Massachusetts.
Rebecca I HartmanHarvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Dermatology Section, VA Integrated Service Network 1 (VISN-1), Jamaica Plain, Massachusetts. Electronic address: rhartman@bwh.harvard.edu.

Funding

Risk Factors for Clinically Aggressive Melanoma in VeteransIK2CX002531 · VA · VA BOSTON HEALTH CARE SYSTEM · PI Rebecca Ivy Hartman · 2024 to 2026
–
CSRD VA IK2 CX002531Intramural VA VA999999
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MelanomaSkin NeoplasmsVeteransAntineoplastic Combined Chemotherapy ProtocolsHumansImmune Checkpoint InhibitorsIpilimumabMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafBRAF protein, humanImmune Checkpoint InhibitorsIpilimumabMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafadjuvantBRAFcobimetinibcutaneousdabrafenibICIimmune checkpoint inhibitorsipilimumabMEKmelanomametastaticnivolumabpembrolizumabreal-worldstage IIIstage IVsystemictargeted therapiesVAvemurafenibveteran

Identifiers

PMID37924953
PMCPMC13491309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.